It’s been a crucial week for Histogenics Corporation (NASDAQ:HSGX); here’s what analysts have to say.

June 20, 2018 - By Stephen Andrade

Histogenics Corporation (NASDAQ:HSGX) Logo

Histogenics Corporation (NASDAQ:HSGX) Ratings Coverage

Among 2 analysts covering Histogenics (NASDAQ:HSGX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Histogenics had 4 analyst reports since December 21, 2017 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Thursday, December 21. H.C. Wainwright maintained the shares of HSGX in report on Wednesday, December 27 with “Buy” rating. The stock of Histogenics Corporation (NASDAQ:HSGX) has “Buy” rating given on Friday, May 11 by H.C. Wainwright. H.C. Wainwright maintained Histogenics Corporation (NASDAQ:HSGX) on Monday, March 19 with “Buy” rating. Below is a list of Histogenics Corporation (NASDAQ:HSGX) latest ratings and price target changes.

11/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5000 Maintain
19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
21/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $4.0 Maintain

The stock decreased 5.24% or $0.15 during the last trading session, reaching $2.71. About 52,868 shares traded. Histogenics Corporation (NASDAQ:HSGX) has risen 41.82% since June 20, 2017 and is uptrending. It has outperformed by 29.25% the S&P500.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $77.74 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Another recent and important Histogenics Corporation (NASDAQ:HSGX) news was published by Globenewswire.com which published an article titled: “Histogenics Corporation to Host Investor Day on June 19, 2018” on May 31, 2018.

Histogenics Corporation (NASDAQ:HSGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: